^
    Back
    Association details:
    Biomarker:DLL3 expression
    Cancer:Neuroblastoma
    Drug:Rova-T (rovalpituzumab tesirine) (DNA replication inhibitor, DLL3-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Cancer Res Commun
    Title:

    Evaluation of the DLL3-targeting Antibody–Drug Conjugate Rovalpituzumab Tesirine in Preclinical Models of Neuroblastoma

    Published date:
    07/11/2022
    Excerpt:
    We first tested the efficacy of Rova-T in four neuroblastoma PDX models using a conventional design of 8–10 mice per arm. In the PDX array, all four of these models had robust DLL3 expression...There was a clear dose–response effect, and all models showed some or significant evidence of antitumor activity at a single 0.6 mg/kg dose (i.e., one injection) of Rova-T...
    DOI:
    https://doi.org/10.1158/2767-9764.CRC-22-0137